prednisolone has been researched along with Metabolic Syndrome in 11 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic prednisolone treatment in renal transplant recipients (RTR) causes metabolic abnormalities, which cluster in the metabolic syndrome (MS)." | 7.85 | Twenty-four hour urinary cortisol excretion and the metabolic syndrome in prednisolone-treated renal transplant recipients. ( Bakker, SJL; Berger, SP; de Jong, WHA; de Vries, LV; Kema, IP; Navis, G; Touw, DJ, 2017) |
| "Men with the metabolic syndrome but without diabetes received prednisolone 30 mg once daily plus sitagliptin 100 mg once daily (n=14), prednisolone (n=12) or sitagliptin alone (n=14) or placebo (n=12) for 14 days in a double-blind 2 × 2 randomized-controlled study." | 5.19 | Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial. ( Diamant, M; Heymans, MW; Mari, A; Muskiet, MH; Ouwens, DM; Pouwels, PJ; van Genugten, RE; van Raalte, DH, 2014) |
| "Chronic prednisolone treatment in renal transplant recipients (RTR) causes metabolic abnormalities, which cluster in the metabolic syndrome (MS)." | 3.85 | Twenty-four hour urinary cortisol excretion and the metabolic syndrome in prednisolone-treated renal transplant recipients. ( Bakker, SJL; Berger, SP; de Jong, WHA; de Vries, LV; Kema, IP; Navis, G; Touw, DJ, 2017) |
| "Treatment of children with congenital adrenal hyperplasia (CAH) with corticosteroids (CS) may increase the risk for developing different components of metabolic syndrome (MetS)." | 1.72 | Growth and Metabolic Syndrome (MetS) criteria in young children with classic Congenital Adrenal Hyperplasia (CAH) treated with corticosteroids (CS). ( Abdel Meguid, SE; Abougabal, AMS; Ahmed, S; De Sanctis, V; Hamed, N; Hassan, M; Ramadan, MAEF; Soliman, AT, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) is nowadays the most common liver disease worldwide." | 1.56 | Non-alcoholic steatohepatitis or autoimmune hepatitis? Sometimes a closer look under the surface is needed. ( Dalekos, GN; Gatselis, NK; Koukoulis, GK, 2020) |
| "Prednisolone dosage was increased from 10 to 60 mg/day." | 1.36 | Type B insulin resistance syndrome with systemic lupus erythematosus. ( Gohda, T; Horikoshi, S; Ohsawa, I; Sato, N; Shirato, I; Takagi, M; Tomino, Y; Yamaguchi, Y, 2010) |
| "Obesity is increasingly prevalent in affluent societies and portends considerable morbidity." | 1.36 | Growth in children with acute lymphoblastic leukemia during treatment. ( Barr, RD; Collins, L; Nayiager, T; Pollock, BH; Zarzabal, LA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel Meguid, SE | 1 |
| Soliman, AT | 2 |
| De Sanctis, V | 2 |
| Abougabal, AMS | 1 |
| Ramadan, MAEF | 1 |
| Hassan, M | 1 |
| Hamed, N | 2 |
| Ahmed, S | 1 |
| Elbaba, M | 1 |
| Alyafei, F | 1 |
| Alaaraj, N | 1 |
| Ahmad, S | 1 |
| Itani, M | 1 |
| Al-Naimi, F | 1 |
| Khater, D | 1 |
| Dalekos, GN | 1 |
| Gatselis, NK | 1 |
| Koukoulis, GK | 1 |
| de Vries, LV | 1 |
| de Jong, WHA | 1 |
| Touw, DJ | 1 |
| Berger, SP | 1 |
| Navis, G | 1 |
| Kema, IP | 1 |
| Bakker, SJL | 1 |
| Jung, SY | 1 |
| Shim, HS | 1 |
| Hah, YM | 1 |
| Kim, SH | 1 |
| Yeo, SG | 1 |
| Wang, B | 1 |
| Smyl, C | 1 |
| Chen, CY | 1 |
| Li, XY | 1 |
| Huang, W | 1 |
| Zhang, HM | 1 |
| Pai, VJ | 1 |
| Kang, JX | 1 |
| van Genugten, RE | 1 |
| van Raalte, DH | 1 |
| Muskiet, MH | 1 |
| Heymans, MW | 1 |
| Pouwels, PJ | 1 |
| Ouwens, DM | 1 |
| Mari, A | 1 |
| Diamant, M | 1 |
| Taniguchi, A | 1 |
| Sato, N | 1 |
| Ohsawa, I | 1 |
| Takagi, M | 1 |
| Gohda, T | 1 |
| Horikoshi, S | 1 |
| Shirato, I | 1 |
| Yamaguchi, Y | 1 |
| Tomino, Y | 1 |
| Collins, L | 1 |
| Zarzabal, LA | 1 |
| Nayiager, T | 1 |
| Pollock, BH | 1 |
| Barr, RD | 1 |
| Sahebari, M | 1 |
| Goshayeshi, L | 1 |
| Mirfeizi, Z | 1 |
| Rezaieyazdi, Z | 1 |
| Hatef, MR | 1 |
| Ghayour-Mobarhan, M | 1 |
| Akhlaghi, S | 1 |
| Sahebkar, A | 1 |
| Ferns, GA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism and Beta-Cell Dysfunction in Males With the Metabolic Syndrome X: A Randomized, Placebo-controlled, Double-blind Intervention Study With a 2x2 Factorial Design[NCT00721552] | 82 participants (Actual) | Interventional | 2008-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for prednisolone and Metabolic Syndrome
| Article | Year |
|---|---|
[Therapy for gout and pseudogout].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Calcium Pyrophosphate; Chondrocal | 2008 |
1 trial available for prednisolone and Metabolic Syndrome
| Article | Year |
|---|---|
Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; F | 2014 |
9 other studies available for prednisolone and Metabolic Syndrome
| Article | Year |
|---|---|
Growth and Metabolic Syndrome (MetS) criteria in young children with classic Congenital Adrenal Hyperplasia (CAH) treated with corticosteroids (CS).
Topics: Adrenal Hyperplasia, Congenital; Carotid Intima-Media Thickness; Child; Child, Preschool; Cholestero | 2022 |
The long-term (five years) effects of prednisone therapy in children with frequently relapsing nephrotic syndrome: A controlled study of anthropometric parameters and metabolic abnormalities.
Topics: Child; Cholesterol; Glucose; Humans; Metabolic Syndrome; Nephrotic Syndrome; Obesity; Prednisolone; | 2022 |
Non-alcoholic steatohepatitis or autoimmune hepatitis? Sometimes a closer look under the surface is needed.
Topics: Adult; Antibodies, Antinuclear; Biopsy; Diagnosis, Differential; Diagnostic Errors; Elasticity Imagi | 2020 |
Twenty-four hour urinary cortisol excretion and the metabolic syndrome in prednisolone-treated renal transplant recipients.
Topics: Female; Humans; Hydrocortisone; Hypothalamus; Kidney Transplantation; Male; Metabolic Syndrome; Midd | 2017 |
Association of Metabolic Syndrome With Sudden Sensorineural Hearing Loss.
Topics: Administration, Oral; Audiometry, Pure-Tone; Cholesterol, HDL; Diabetes Complications; Female; Gluco | 2018 |
Suppression of Postprandial Blood Glucose Fluctuations by a Low-Carbohydrate, High-Protein, and High-Omega-3 Diet via Inhibition of Gluconeogenesis.
Topics: Alanine; Alanine Transaminase; Animals; Blood Glucose; Carbon Isotopes; Diabetes Mellitus, Experimen | 2018 |
Type B insulin resistance syndrome with systemic lupus erythematosus.
Topics: Biopsy; Dose-Response Relationship, Drug; Follow-Up Studies; Glucocorticoids; Humans; Insulin; Insul | 2010 |
Growth in children with acute lymphoblastic leukemia during treatment.
Topics: Antineoplastic Agents, Hormonal; Body Mass Index; Child; Child, Preschool; Combined Modality Therapy | 2010 |
Investigation of the association between metabolic syndrome and disease activity in rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Femal | 2011 |